ALX Oncology Holdings Inc
ALXO
查看详细走势图
1.865USD
-0.175-8.58%
交易中 （美东）报价延迟15分钟
74.31M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-8.58%
5天
-14.45%
1月
-11.61%
6月
+6.57%
今年开始到现在
+65.04%
1年
+184.69%
查看详细走势图
TradingKey ALX Oncology Holdings Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
ALX Oncology Holdings Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名93/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.60。中期看，股价处于上升通道。近一个月，市场表现一般，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
ALX Oncology Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
ALX Oncology Holdings Inc亮点
亮点风险
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
估值合理
公司最新PE估值-1.08，处于3年历史合理位
机构加仓
最新机构持股35.78M股，环比增加1.57%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值1.63M
活跃度增加
近期活跃度增加，过去20天平均换手率0.59
分析师目标
根据
7
位分析师
买入
评级
4.600
目标均价
+125.49%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
ALX Oncology Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ALX Oncology Holdings Inc简介
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
公司代码ALXO
公司ALX Oncology Holdings Inc
CEOLettmann (Jason)
网址https://alxoncology.com/
相关品种
